Results 71 to 80 of about 5,310 (124)

DapPep: Domain Adaptive Peptide-agnostic Learning for Universal T-cell Receptor-antigen Binding Affinity Prediction [PDF]

arXiv
Identifying T-cell receptors (TCRs) that interact with antigenic peptides provides the technical basis for developing vaccines and immunotherapies. The emergent deep learning methods excel at learning antigen binding patterns from known TCRs but struggle with novel or sparsely represented antigens.
arxiv  

The Encapsulation Strategies for Targeted Delivery of Probiotics in Preventing and Treating Colorectal Cancer: A Review

Advanced Science, EarlyView.
This work summarizes the efficacy and mechanisms of probiotics in CRC treatment, providing a comprehensive overview of various encapsulation methods such as microcapsules, hydrogels, single‐cell nanocoatings, and nanofibers for targeted probiotic delivery to inflammatory sites, with particular emphasis on the potential advantages of emerging single ...
Hao Zhong, Jin Jiang, Muhammad Hussain, Haoxuan Zhang, Ling Chen, Rongfa Guan   +5 more
wiley   +1 more source

Functional Materials Targeted Regulation of Gasdermins: From Fundamentals to Functionalities and Applications

Advanced Science, EarlyView.
Targeted regulation of pyroptosis to modulate the immune landscape is a novel design strategy for cancer immunotherapy and anti‐inflammatory treatment. Pyroptosis, as a double‐edged sword, underscores the importance of optimizing the design strategy of functional materials and appropriately activating pyroptosis for the effective treatment of diseases.
Luyao Tian, Shuo Piao, Xia Li, Lanping Guo, Luqi Huang, Wenyuan Gao   +5 more
wiley   +1 more source

IL‐33‐Induced TREM2+ Macrophages Promote Pathological New Bone Formation Through CREG1‐IGF2R Axis in Ankylosing Spondylitis

Advanced Science, EarlyView.
This study identifies TREM2+ macrophages as key contributors to pathological bone formation in ankylosing spondylitis (AS). These macrophages mediate pathological new bone formation via the CREG1‐IGF2R‐PI3K‐AKT pathway and are regulated by IL‐33 through STAT6 phosphorylation.
Wenjun Hao, Siwen Chen, Hua Chao, Zihao Li, Hao Yang, Dongying Chen, Sifang Li, Shuai Zhang, Jingyu Zhang, Jianru Wang, Zemin Li, Xiang Li, Zhongping Zhan, Tangming Guan, Yiwen Zhang, Wende Li, Hui Liu   +16 more
wiley   +1 more source

Clinical Relevance of Drug–Drug Interactions With Antibiotics as Listed in a National Medication Formulary: Results From Two Large Population‐Based Case‐Control Studies in Patients Aged 65–100 Years Using Linked English Primary Care and Hospital Data

Clinical Pharmacology &Therapeutics, Volume 113, Issue 2, Page 423-434, February 2023., 2023
This study evaluated drug–drug interactions (DDIs) between antibiotic and nonantibiotic drugs listed with warnings of severe outcomes in the British National Formulary based on adverse drug reaction (ADR) detectable with routine International Classification of Diseases, Tenth Revision coding.
Tjeerd Pieter van Staa, Munir Pirmohamed, Anita Sharma, Iain Buchan, Darren M. Ashcroft   +4 more
wiley   +1 more source

Neoadjuvant Chemotherapy With Cisplatin Up‐Regulates GSDMD to Enhance Oral Squamous Cell Carcinoma Metastasis Through MMP14‐Mediated EMT Activation

Advanced Science, EarlyView.
Oral squamous cell carcinoma cells exhibit upregulated expression of GSDMD upon exposure to low‐dose cisplatin chemotherapy, which subsequently interacts with MMP14 through its N‐terminal domain, activating the epithelial‒mesenchymal transition (EMT) process and promoting the lymph node metastasis of oral squamous cell carcinoma.
Zixian Huang, Qiming Jiang, Qianyu Zhang, Nan Lu, Xi Rui, Rui Chen, Yan Wang, Yuepeng Wang, Xiaoding Xu, Zhiquan Huang   +9 more
wiley   +1 more source

Epithelial PD‐L1 expression at tumor front predicts overall survival in a cohort of oral squamous cell carcinomas from Sudan

Clinical and Experimental Dental Research, Volume 8, Issue 6, Page 1467-1477, December 2022., 2022
Abstract Background We recently described the tumor immune microenvironment (TIME) in oral squamous cell carcinomas (OSCC) from Sudan by assessing the core of the lesions. However, the invasive tumor front (ITF) is the most active part of OSCC lesions; thus, TIME should also be characterized at the ITF in this patient cohort.
Nuha M. Gaafar, Tarig Al‐Hadi Osman, Mariam Elsheikh, Israa Abdulrahman Ahmed, Harsh Dongre, Siren Fromreide, Ahmed M. Suleiman, Anne C. Johannessen, Elisabeth S. Nginamau, Daniela‐Elena Costea   +9 more
wiley   +1 more source

Fragment Autoantigens Stimulated T‐Cell‐Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine

Advanced Science, EarlyView.
A personalized whole tumor cell vaccine (FAST) is developed to address immunosuppressive tumor microenvironments and genomic instability‐driven heterogeneity. Irradiation and cryoablation‐treated tumor cells generate fragmented antigens (FAs) that activate broad‐spectrum antigen presentation via upregulated immunogenic cell death, MHC‐I, and damage ...
Yuan Li, Huiqin Chen, Qiaofeng Shen, Yingshuang Liu, Pingping Li, Yuqi Ma, Yugang Wang, Shengkai Li, Xueqing Yan, Liyu Liu, Jianwei Shuai, Min Wu, Qi Ouyang, Feng‐Ming (Spring) Kong, Gen Yang   +14 more
wiley   +1 more source

Recent Advances in Enhancing the Sensitivity of Biosensors Based on Field Effect Transistors

Advanced Electronic Materials, EarlyView.
This paper discusses the methods to enhancing the detection sensitivity of biosensors in three aspects: overcoming the influence of Debye shielding effects, promoting the binding efficiency of analytes and transistor surface, and improving the structures of device.
Yuying Zhou, Tongshi Feng, Yao Li, Xiang Ao, Shengfa Liang, Xiaonan Yang, Lingfei Wang, Xiaoxin Xu, Wenchang Zhang   +8 more
wiley   +1 more source

An Asymptotic Analysis of Bivalent Monoclonal Antibody-Antigen Binding [PDF]

arXiv
Ligand-receptor interactions are fundamental to many biological processes. For example in antibody-based immunotherapies, the dynamics of an antibody binding with its target antigen directly influence the potency and efficacy of monoclonal antibody (mAb) therapies.
arxiv